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Introduction
Oxidative and nitrosative radicals have been associated with the
development of myocardial tissue injury during chronic heart
failure, reperfusion that follows ischaemia and in response to
inflammatory cytokines or cardiotoxic drugs [1–9]. Under these
pathologic conditions, various protein and lipid molecules serve
as targets for the accumulating oxidative and/or nitrosative agents
[10, 11]. Proteins of the sarcomere are of special interest because
their alterations will influence the structure and/or the regulation
of the interaction between the thin and the thick myofilaments, and
thereby will affect directly the conversion of chemical energy into
force and shortening [12, 13].
Peroxynitrite, a metabolite of nitric oxide, is frequently cited as
one of the most damaging nitrosative agents [2, 4, 14], although
peroxynitrite is not necessarily toxic as basal peroxynitrite forma-
tion may have several physiological roles [15]. Oxidation of protein
tyrosine residues by peroxynitrite results in nitrotyrosine forma-
tion, which is considered as a hallmark of the peroxynitrite-evoked
protein damage [16]. However, reactive nitrogen species also react
with the thiol groups (SH) of cysteinil residues and thus, may
induce the formation of disulfide bonds [8, 17, 18]. It is worthy for
consideration, that while the generation of nitrotyrosine side chains
is considered to be irreversible, the oxidation of SH groups is
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In this study, we aimed to determine the contribution of peroxynitrite-dependent sulfhydryl group (SH) oxidation to the contractile dysfunc-
tion in permeabilized left ventricular human cardiomyocytes using a comparative approach with the SH-oxidant 2,2-dithiodipyridine
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to test reversibility. Maximal isometric active force production (Fo) and the maximal turnover rate of the cross-bridge cycle (ktr,max) illus-
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lation. Both peroxynitrite and DTDP diminished Fo in a concentration-dependent manner (EC50,peroxynitrite  49 M; EC50,DTDP 
2.75 mM). However, ktr,max was decreased only by 2.5-mM DTDP, but not by 50 M peroxynitrite. The diminution of Fo to zero by DTDP
was paralleled by the complete elimination of the free SH groups, while the peroxynitrite-induced maximal reduction in free SH groups
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Fo or ktr,max after DTDP treatments. Our results revealed that the peroxynitrite-evoked cardiomyocyte dysfunction has a small, but
 significant component resulting from reversible SH oxidation, and thereby illustrated the potential benefit of antioxidants during cardiac
pathologies with excess peroxynitrite production.
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2reversible. Hence, antioxidants may theoretically prevent or revert,
at least part of the peroxynitrite-evoked protein changes [19].
Importantly, both the tyrosine residues [2] and the protein SH
groups were found to undergo marked changes during ischaemia
and reperfusion [20, 21]. Moreover, both the amounts of nitration
and SH oxidation of proteins have been associated with the
contractile depression in various myocardial preparations of
animal and human hearts [4, 5, 22, 23]. Nevertheless, the relative
contribution of SH oxidation to the peroxynitrite-evoked contrac-
tile dysfunction is unknown.
In this study, we made attempts to elucidate the SH-oxidizing
potential of peroxynitrite, and to determine the reversibility of per-
oxynitrite-dependent mechanical alterations in human cardiomy-
ocytes. To these ends, permeabilized left ventricular cardiomy-
ocytes were incubated in the presence of peroxynitrite, which has
hypothetically effects both on protein SH groups and on tyrosine
residues. In parallel assays, 2,2 dithiodipyridine (DTDP) was
employed as a selective SH-oxidant [24]. In addition, dithiothreitol
(DTT), reduced glutathione (GSH) or N-acetyl-cysteine (NAC) were
applied as reducing agents to test reversibility. Maximal Ca2-acti-
vated force (Fo) and the cross-bridge-specific rate constant of force
redevelopment at saturating Ca2 concentration (ktr,max) were
monitored along with these incubations, and were considered as
indicators of the actin-myosin interactions. Additionally, the Ca2-
independent passive force component (Fpassive) was also assessed.
Furthermore, biochemical assays were performed to determine the
SH-specificity of the reagents and to evaluate the involvement of
myocardial proteins in parallel with the mechanical changes.
Our results illustrate myofilament SH-oxidation as a potential
mechanism contributing to the peroxynitrite-evoked mechanical
dysfunction of human cardiomyocytes. Moreover, our data are
also suggestive for a complex interplay between the chemical
characteristics of the applied oxidative and reducing agents and
the mechanical function of human cardiomyocytes.
Materials and methods
Ethical approval
The experiments on human tissues complied with the Helsinki Declaration
of the World Medical Association and were approved by the Hungarian
Ministry of Health (No. 323-8/2005-1018EKU) and by the Institutional
Ethical Committee at the University of Debrecen, Hungary (No. DEOEC
RKEB/IKEB 2553-2006).
Human left ventricular tissue samples,
permeabilized cardiomyocytes
Human donor hearts obtained from 5 general organ donor patients (male
and female donors between 37 and 56) were explanted to obtain pulmonary
and aortic valves as homografts for cardiac surgery. The donors did not
reveal any sign of cardiac abnormalities and had not received any medication
except short-term dobutamine and furosemide. The cause of death was
cerebral contusion and cerebral haemorrhage due to accidents or subarach-
noid haemorrhage. Biopsies were transported in cardioplegic solution (pH
7.4; in mM): NaCl 110, KCl 16, MgCl2 1.6, CaCl2 1.2, NaHCO3 5 and kept at
4	C for ~1–4 hrs before being frozen in liquid nitrogen and stored at 
80	C.
Frozen tissue samples were defrosted and mechanically disrupted in
isolation solution (composition in mM: MgCl2 1, KCl 145, EGTA 2, ATP 4,
imidazole 10; pH 7.0). The resultant suspension was incubated in isolation
solution supplemented with 0.5% Triton X- 100 (Sigma, St. Louis, MO,
USA) for 5 min. to permeabilize all the membranous structures. The prepa-
rations were washed three times (centrifugation with 1000 rpm for 1 min.
and subsequently kept at 4	C till the following experiments.
Mechanical properties of cardiomyocytes, in vitro
applications of oxidative and reducing agents
Permeabilized single cardiomyocyte preparations were mounted between
two thin needles with silicone adhesive (Dow Corning, Midland, MI, USA)
while viewed under an inverted microscope (Axiovert 135, Zeiss, Germany)
[25, 26]. The advantage of these preparations is that they present negligi-
ble diffusion obstacles, allowing almost instantaneous equilibration of
oxidative and reducing agents between the bathing medium and the pro-
teins of the cardiomyocytes. One needle was attached to a force transduc-
er (SensoNor, Horten, Norway) and the other to an electromagnetic motor
(Aurora Scientific Inc., Aurora, Canada). The force measurements were
performed at 15	C, and the average sarcomere length was adjusted to 
2.2 m as described previously [27].
The compositions of the relaxing and activating solutions used during
force measurements were calculated as described earlier [28, 29]. The pCa
(
log[Ca2]) values of the relaxing and activating solutions (pH 7.2) were
9 and 4.75, respectively. All the solutions for force measurements con-
tained (in mM): Mg2 1, MgATP 5, phosphocreatine 15 and N,N-bis(2-
hydroxyethyl)-2-aminoethanesulfonic acid 100. The ionic equivalent was
adjusted to 150 mM with KCl resulting in an ionic strength of 186.
Fo, Fpassive and ktr,max were determined as described earlier [25]. These
contractile parameters were measured under both control (before peroxyni-
trite or DTDP) and test conditions (i.e. after exposure to various oxidative
and/or reducing agents). Concentrated stock solutions of peroxynitrite
(Calbiochem, San Diego, CA, USA) were prepared based on peroxynitrite
 concentration determination by absorbance measurements at 302 nm. The
pH in stock solutions was adjusted to 11 (by KOH) to oppose peroxynitrite
decomposition. A single volume of 20 l from these stock solutions was rap-
idly introduced into a droplet (180 l) of relaxing solution (pH 7.2, T  22	C),
which surrounded each myocyte preparation in the mechanical set-up. This
approach resulted in nominal peroxynitrite concentrations ranging from 1 to
1000 M, which decreased quickly because of spontaneous degradation
(half-life: less than 3 sec. in our system). Peroxynitrite exposure was termi-
nated following 60 sec. of incubation. Control force measurements suggest-
ed that non-specific effects due to hydrogen peroxide contamination or the
by-products of peroxynitrite (i.e. nitrite or nitrate) have a very limited role, if
any in our system. Incubations in the presence of other oxidative and reducing
agents were also performed in droplets of 200 l volumes of relaxing solu-
tions. Incubations with DTDP (Sigma) lasted for 2 min., however with 
10-mM DTT (Eastman Kodak Company, Rochester, MN, USA), 10-mM GSH
or 100-mM GSH (Sigma) or 10-mM NAC or 100-mM of NAC (Sigma) these
were extended for 30 min. (all at 22	C). Results of control measurements
and literature data suggested that these durations were sufficient to reach
steady-state changes in the SH status of our preparations (data not shown).
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To assess the concentration dependences of peroxynitrite or DTDP on
Fo the cardiomyocytes were exposed to a series of solutions with various
concentrations of peroxynitrite or DTDP at pCa 9.0, and subsequently to
pCa 4.75 without peroxynitrite or DTDP. In a different set of experiments,
the determination of control Fo was followed by the exposures to 2.5-mM
DTDP or 50-M peroxynitrite and thereafter DTT, GSH or NAC was applied
to test reversibility. To determine the effect of run-down and the stability of
our preparations control measurements (in n  4–6 cardiomyocytes) with
the same number of activations as with the oxidative and/or reducing
agents were performed without any chemicals. During these control exper-
iments Fo decreased at maximum to 82  1% (mean  S.E.M.; P  0.05),
ktr,max to 81  5% (P  0.05), while Fpassive was stable (i.e. at the end of
test runs it was 100  3% of the initial value, P  0.05).
Quantitative determination of the SH status of
myofilament proteins
To determine the SH content, permeabilized cardiomyocytes (prepared
similarly to the mechanical measurements) were treated with the different
oxidative and/or reducing agents in isolation buffer at a protein concentra-
tion of 5 mg/ml at 22	C. Then SH content was determined by incubation
with the SH-sensitive Ellman’s reagent (5,5-dithio-bis(2-nitrobenzoic
acid); Sigma)) for 15 min. at 22	C [30]. The absorbance of the solutions at
412 nm was considered to be proportional to their SH contents. The sam-
ples were assessed via calibration curves (standards: N-acetyl-L-cysteine
and reduced glutathione; both from Sigma) fitted to a single exponential,
and the SH contents of the cardiac samples were calculated.
Qualitative analysis of SH groups oxidized in
myofilament proteins
To analyse the sensitivity of certain myocardial proteins to SH oxidizing
agents, permeabilized cardiomyocytes were incubated in the presence of
DTDP (up to 2.5 mM) or peroxynitrite (up to 1000 M) in relaxing solution
and subsequently in the presence of DTT, GSH or NAC to test reversibility.
Then, the reagents were removed by three washing steps and the protein
concentrations were adjusted to 5 mg/ml. Subsequently, preparations were
incubated in the presence of 60 M ()-biotinyliodoacetamidyl-3,
6-dioxaoctanediamine (Pierce, Rockford, IL, USA) at 22	C for 90 min. to
biotinylate the SH groups of the proteins. After biotinylation, the prepara-
tions were washed in isolation buffer three times, and boiled in SDS-PAGE
loading buffer (Sigma). The protein concentrations were tested by a dot
blot-based method; thereafter 25 g protein homogenates were applied to
10% gels or to 6–18% gradient gels (Biorad, Hercules, CA, USA) and sub-
sequently transferred to nitrocellulose membranes. The membranes were
blocked in 5% milk powder (1 hr) and then incubated with a streptavidin-
peroxidase conjugate (Vector Laboratories, Burlingame, CA, USA) for 30 min.
Bands representing biotinylated proteins at their free (reduced) SH groups
were recorded on autoradiographic films (Primax RTG-B, Berlin,
Germany), resulting in dark signals. Signal intensities were considered to
be proportional with the free SH group contents of the respective proteins.
Data analysis
Statistical significance was calculated by analysis of variance (ANOVA,
repeated measures) and, where applicable, by Student’s t-test. Values are
given as means  S.E.M. The number of experiments in each group
 varied between 3 and 31 from three to five different hearts. Statistical
 significance was accepted at P  0.05.
Results
Both peroxynitrite and DTDP decreased Fo to zero in permeabilized
human ventricular cardiomyocytes in a concentration-dependent
manner (Fig. 1A). In case of peroxynitrite, the force diminution was
noticed in the M concentration range (EC50,peroxynitrite  49 M),
while DTDP exerted its mechanical effect at higher concentrations
(EC50,DTDP  2.75 mM). To elucidate the SH-oxidizing effect of
peroxynitrite and DTDP, parallel biochemical assays were
performed with the SH-sensitive Ellman’s reagent. Of note, the
experimental conditions, including temperature for the Ellman’s
assays and mechanical measurements, were comparable. Figure 1B
illustrates that increasing concentrations of DTDP decreased the
SH content of the myocardial proteins to zero along with the
diminution of force. On the contrary, peroxynitrite-evoked signifi-
cant SH oxidation only at very high concentrations: the fraction of
reduced SH groups decreased to 58  7% (P  0.05) of that of
the untreated control (100%) following the application of 1-mM
peroxynitrite.
Previous experimental studies revealed interactions between
protein kinase A-mediated intracellular signalling and protein SH
oxidation [31, 32]. To address if the short-term dobutamie pre-
medication had an effect on SH oxidation of the myocardial pro-
teins, we compared the SH contents of the myocardial proteins
before and after incubations in the presence of 10-mM DTT, 
100-mM NAC or 100-mM GSH. Results of these assays did not
differ significantly from those of untreated controls and from each
other, and collectively they gave a relative level of SH content of
101.7  8.2%. Hence, these data argued against a hypothetical
protein oxidation by dobutamine.
Having established that SH oxidation associates with the dete-
rioration of contractile force, the parameters of cardiomyocyte
mechanics (Fo, ktr,max and Fpassive) were investigated at a single
peroxynitrite concentration (50 M) resulting in about half maxi-
mal reduction in Fo (Fig. 2). Fo declined to 56  4% of the control
after the application of 50 M peroxynitrite (Fig. 2B), however
Fpassive and ktr,max did not change significantly (Fig. 2C and D). To
estimate the relative contribution of SH oxidation besides other
types of potential protein modifications to the reduction in Fo,
SH-specific reducing agents were employed to reverse SH oxida-
tion. Figure 2B illustrates that indeed both 10-mM DTT and
10-mM NAC were able to evoke partial, although significant,
increases in Fo in peroxynitrite-treated cardiomyocytes, suggest-
ing that this increase was specific for the reduction of protein
SH groups. Fo was increased to 69  4% of the control by 10-mM
DTT (P  0.05 versus Fo,peroxynitrite), and the relative increase in 
Fo was to 71  7% of the control by 10-mM NAC (P  0.05 ver-
sus Fo,peroxynitrite). Fpassive did not change following 10-mM DTT or
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410-mM NAC in peroxynitrite-treated cardiomyocytes (Fig. 2C). Of
note, ktr,max decreased slightly following 10-mM DTT or 10-mM NAC
applications in peroxynitrite-treated cardiomyocytes. However,
based on control experiments with repeated activations in the
absence of any chemicals, this small decrease in ktr,max was prob-
ably related to preparation run-down.
The partial contribution of SH oxidation to the peroxynitrite-
evoked force reduction was confirmed by biochemical methods
(Fig. 3). Results of Ellman’s assays showed that 1-mM peroxyni-
trite (a peroxynitrite concentration with maximal SH oxidative
effect, Fig. 1B) decreased the free SH content to 58  7%, which
was completely reversed by 10-mM DTT. SH content after 1-mM
peroxynitrite  10-mM DTT was 94  5% (P  0.05 versus
1-mM peroxynitrite). Surprisingly, when applied at the 10-mM
concentration the effects of GSH or NAC did not reach significance
on the overall free SH content of the myocardial protein prepara-
tions. SH content after 1-mM peroxynitrite  10-mM GSH was 
65  6%, and SH content after 1-mM peroxynitrite  10-mM NAC
was 64  6% (P  0.05 versus 1-mM peroxynitrite). However,
when the same reducing agents were employed at a concentration
of 100 mM, both of them reduced protein SH groups effectively.
Protein SH content after 1-mM peroxynitrite  100-mM GSH was
105  15% and SH content after 1-mM peroxynitrite  100-mM
NAC was 118  14% (P  0.05 versus 10-mM peroxynitrite; 
Fig. 3A). An effort was also made to identify whether certain pro-
teins undergo selective oxidation-reduction cycles during the
incubations with the various drug combinations. SH-specific
biotinylation, however, suggested a uniform decrease in the free
SH group-specific staining intensity of myocardial proteins with
different molecular weights at the highest peroxynitrite concentra-
tion (1 mM). Moreover, these changes were fully reversed by 
10-mM DTT, and only to a smaller degree by 10-mM GSH or 10-mM
NAC (Fig. 3B). Therefore, the results of these assays were remi-
niscent of the results of the Ellmans’s test, but failed to identify
peroxynitrite-specific selective myocardial protein oxidation.
As a next step, the effects of DTDP-evoked SH oxidation were
compared to the peroxynitrite-induced alterations. The Ellman’s
assay indicated that 2.5-mM DTDP (a DTDP concentration with a
comparable effect on Fo to that of 50 M peroxynitrite, Fig. 1A)
resulted in a robust decrease in the myocardial free SH content
(i.e. it decreased to 14  2%; Fig. 4A), which was reversed either
completely (by DTT) or partially (by GSH or NAC) when the antiox-
idants were all used at the same 10-mM concentration. SH con-
tent after 2.5-mM DTDP  10-mM DTT was 97  14%, SH con-
tent was 34  8% after 2.5-mM DTDP  10-mM GSH, and it was
30  4% after 2.5-mM DTDP  10-mM NAC (for all P  0.05
versus 2.5-mM DTDP). Moreover, 100-mM GSH or 100-mM NAC
reduced 2.5-mM DTDP-oxidized myocardial proteins more effec-
tively than 10-mM GSH or 10-mM NAC. SH content after 2.5-mM
DTDP  100-mM GSH was 79  3%, whereas it was 68  15%
after 2.5-mM DTDP  100-mM NAC (for both P  0.05 versus
2.5-mM DTDP). To compare the effects of antioxidants at a simi-
lar level of DTDP-evoked SH oxidation as occurred after the appli-
cation of 1-mM peroxynitrite, the above tests were also repeated
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Fig. 1 Changes in Fo and human myocardial
protein SH content with the application of
increasing concentrations of peroxynitrite or
DTDP. (A) The concentration-effect relation of
peroxynitrite (•) and DTDP ( ) on Fo.
Peroxynitrite and DTDP, both abolished Fo in a
concentration-dependent manner but in differ-
ent concentration ranges. (B) The concentra-
tion-effect relation of peroxynitrite (•) and
DTDP ( ) on the relative amount of myocar-
dial-free SH groups (untreated control:
100%). DTDP oxidized all myocardial protein
SH groups in the same concentration range
where Fo diminished. In contrast, peroxynitrite
evoked only a partial reduction in the amount
of free SH groups even at the highest
employed peroxynitrite concentration.
Symbols denote means  S.E.M. when larger
than symbol size. The curves connecting the
mean values in A and B were constructed by
eye and serve illustrative purposes (n  20
cardiomyocytes for peroxynitrite; n  4 car-
diomyocytes for DTDP). * Marks significant
differences versus controls.
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following incubations in the presence of 0.1-mM DTDP (Fig. 4B).
0.1-mM DTDP decreased myocardial-free SH content to 57 
12%, which was reversed completely by 10-mM DTT (i.e. to 118
 20%). The effects of the other two reducing agents GSH and
NAC did not reach significance when they were applied at the 
10-mM concentration. SH content was 72  6% after 0.1-mM
DTDP  10-mM GSH, and it was 61  5% after 0.1-mM DTDP 
10-mM NAC (for all P  0.05 versus 0.1-mM DTDP). However,
when GSH or NAC were employed at a concentration of 100 mM,
both of them reduced SH groups completely. SH content was 123
 15% after 0.1-mM DTDP  100-mM GSH, and it was 102 
8% after 0.1-mM DTDP  100-mM NAC (for both P  0.05 ver-
sus 0.1-mM DTDP). Collectively, the results of Ellman’s assays at
similar levels of (peroxynitrite-evoked or DTDP-evoked) protein 
SH oxidation suggested identical characteristics for the employed
antioxidants irrespectively of the molecular nature of the oxidizing
agents. Interestingly, the assays involving protein biotinylation
revealed that DTDP oxidation did not affect all of the myofibrillar
proteins uniformly (Fig. 4C). Reduced SH groups in some proteins
were apparently more resistant to DTDP (bands still present at
2.5-mM DTDP) than in others. In agreement with the results of
Figure 4A, 10-mM DTT apparently reduced the SH groups of 
all proteins, however 10-mM GSH and 10-mM NAC were only 
partially effective.
Finally, the effects of 2.5-mM DTDP-evoked SH oxidation on
the contractile parameters and on their reversibility were tested
(Fig. 5). 2.5-mM DTDP decreased Fo to 64  2% (P  0.05 ver-
sus control), and ktr,max from a control value of 1.05  0.05 s
1
to 0.78  0.05 s
1 (P  0.05), and induced a modest increase in
Fpassive in some but not in all experiments. Similarly to the perox-
ynitrite-evoked SH oxidation, the DTDP-evoked biochemical and
mechanical effects were largely reversed by 10-mM DTT, suggest-
ing that DTT treatment may be a preferred choice to assess the
contribution of protein SH oxidation to the contractile dysfunction
under various experimental conditions. As a matter of the different
effectiveness for the employed reducing agents, other proofs were
also found. While 10-mM DTT seemed to be suitable to reverse SH
oxidation and contractile mechanics, 10-mM GSH or 10mM NAC
worsened the mechanical effects of 2.5-mM DTDP: the elevations
in Fpassive were further elevated, the decreased Fo was further
decreased, and the ktr,max was slower after GSH and NAC treat-
ments than before.
Discussion
In this study, we investigated the contribution of SH oxidation to
the development of peroxynitrite-mediated contractile dysfunction
using human permeabilized cardiomyocytes. Results of in vitro
experiments revealed that the potential of peroxynitrite to evoke
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Fig. 2 Partial reversion of the
mechanical effects evoked by 
50 M peroxynitrite following
the applications of SH-reducing
agents. (A) Original recordings
illustrate the mechanical effects
of the sequentially applied 50 M
peroxynitrite and 10-mM DTT
(upper panel) and 50 M perox-
ynitrite and 10-mM NAC (lower
panel). Bar graphs (means 
S.E.M.) illustrate the magnitudes
of relative changes in Fo
(B), Fpassive (C) and in ktr,max
(D). Peroxynitrite decreased Fo,
but did not affect Fpassive and
ktr,max. DTT or NAC induced only
a partial reversion in Fo perox-
ynitrite. Control values for Fo,
Fpassive and ktr,max were 28.6 
1.8 kN/m2; 2.26  0.18 kN/m2;
1.02  0.02 1/sec., respectively.
The number of cardiomyocytes
ranged between 12 and 31 for
the different tests.
6SH oxidation is moderate but significant. Nevertheless, the SH oxi-
dation-dependent component of peroxynitrite-evoked alterations
in Ca2-regulated force production proved to be reversible.
Previous investigations pointed to the significance of protein
SH groups in the maintenance of optimal intracellular redox envi-
ronment and their involvement in cell defence against oxidative
damage [20, 33–35]. In order to assure normal biological func-
tion, most cysteinil residues are maintained in a fully reduced
state under physiological conditions [23, 36]. The reversible con-
version of SH groups to disulfides is one of the earliest events
during radical-mediated oxidation of proteins [37]. Myocardial
protein SH content decreases characteristically during ischaemia
and reperfusion, and SH oxidation of proteins may thereby con-
tribute to the contractile dysfunction of the postischaemic
stunned myocardium [20, 36, 38]. Some of the most important
reactive species: the superoxide, H2O2 and peroxynitrite have
been shown to directly cause SH oxidation in protein model sys-
tems and in cells [39, 40]. Our results with the SH-specific DTDP
indicated that oxidation of myocardial SH groups has the potential
to diminish contractile force. Collectively, these considerations
underline the significance of SH oxidation of myocardial proteins,
because marked oxidation of SH groups means not only the
impairment of the first line of the antioxidant cell defence but also
a potential danger for the contractile function.
In this study, we determined the SH oxidation-dependent com-
ponent of peroxynitrite-evoked mechanical alterations in human
cardiomyocytes and compared these effects with that of the SH-
specific DTDP. 50-M peroxynitrite decreased Fo approximately to
50%. DTT or NAC increased Fo significantly following 50-M per-
oxynitrite, and hence identified an SH sensitive component of the
peroxynitrite-induced mechanical dysfunction. A possible expla-
nation for the finding that 10-mM NAC apparently did not reverse
peroxynitrite-induced SH oxidation (Fig. 3) but it did reverse per-
oxynitrite-reduced Fo values (Fig. 2B) may relate to a lower signal
to noise ratio for the Ellman’s assay than that for the mechanical
measurements. Of note, 2.5-mM DTDP evoked a robust reduction
in protein SH content and hence allowed the recognition of
changes in the SH-oxidative status of proteins following 10-mM
NAC or 10-mM GSH exposures (Fig. 4A). However, at lower levels
of protein oxidation that occurred either after 1-mM peroxynitrite
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Fig. 3 Results of biochemical tests assessing myocardial protein SH-oxidation in response to 1-mM peroxynitrite exposures and subsequent applica-
tions of different reducing agents. (A) Bar graphs (means  S.E.M.) illustrate the relative amounts of free (reduced) protein SH groups (untreated con-
trol: 100%) as resulted from the Ellman’s assay. 1-mM peroxynitrite evoked a marked reduction in protein SH content, and 10-mM DTT, 100-mM GSH
or 100-mM NAC gave rise to a full reversion in the total SH content after peroxynitrite. 10-mM GSH or 10-mM NAC were much less effective in reduc-
ing the peroxynitrite-oxidized SH groups than 10-mM DTT or 100-mM GSH or 100-mM NAC. Results are pooled from 9 independent Ellman’s assays.
(B) SH-oxidation of individual myocardial proteins. Identical amounts of myocardial proteins were subjected to SDS-PAGE following SH-specific biotiny-
lation. Signal intensity of the immunoblotted proteins is proportional with the amount their free SH groups as revealed by the Western analysis. SH oxi-
dation of myocardial proteins at all molecular weights was noticed following the application of 1-mM peroxynitrite. Subsequent application of 10-mM
GSH, 10-mM NAC or 10-mM DTT gave similar results with the Ellman’s assays. Assays of panel B were repeated 6 times.
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(Fig. 3A) or after 0.1-mM DTDP (Fig. 4B), the increase in protein
SH content did not reach significance either after 10-mM NAC or
after 10-mM GSH, but only after the application of 100-mM NAC,
100-mM GSH or 10-mM DTT. Taken together, these results sug-
gest that NAC and also GSH are capable to reverse peroxynitrite-
induced SH oxidation, and that Fo is more sensitive for this rever-
sion than protein SH content as evidenced by our Ellman’s assay.
When the SH-specific reducing agent DTT was applied after
DTDP we observed full normalization in the SH content as well
as in Fo and ktr,max. However, when DTT was applied after perox-
ynitrite, although it also reverted SH oxidation, it induced only a
partial restoration in Fo. The full reversion of the free SH groups
following DTDP or peroxynitrite illustrated DTT as a potent SH
reducing agent, but it also pointed to the limited contribution of
SH-oxidation to the mechanical dysfunction of peroxynitrite-
treated cardiomyocytes.
Collectively, it appears that the mechanical alterations following
peroxynitrite applications are attributable to a lesser degree to SH
oxidation than to other types of protein alterations. The partial
restoration in Fo by DTT in cardiomyocytes treated with 50 M
peroxynitrite suggested that the contribution of SH-oxidation can-
not be more than ~20% of the total reduction in Fo. Nevertheless,
it should be pointed out that our assays were performed at room
temperature and at more physiological temperatures the SH oxida-
tion by peroxynitrite or DTDP can be different [41].
Results of earlier investigations from our laboratory demon-
strated that the peroxynitrite-evoked force reduction is best paral-
leled by the nitration of a structural sarcomeric protein, -actinin
Fig. 4 Results of biochemical tests assessing myocardial protein SH-oxidation in response to DTDP exposures and subsequent applications of differ-
ent reducing agents. (A) Bar graphs (means  S.E.M.) illustrate the relative amounts of free (reduced) protein SH groups (untreated control: 100%) as
resulted from the Ellman’s assay. 2.5-mM DTDP evoked a robust reduction in protein SH content, and 10-mM DTT, 100-mM GSH or 100-mM NAC gave
rise to reversion to a large degree in the total SH content after 2.5-mM DTDP. 10-mM GSH or 10-mM NAC were much less effective in reducing the
DTDP-oxidized SH groups than 10-mM DTT, 100-mM GSH or 100-mM NAC. (B) 0.1-mM DTDP evoked comparable reduction in protein SH content to
1-mM peroxynitrite, and 10-mM DTT, 100-mM GSH or 100-mM NAC gave rise to full reversion in the total SH content after 0.1-mM DTDP. 10-mM GSH
or 10-mM NAC were less effective in reducing the DTDP-oxidized SH groups than 10-mM DTT, 100-mM GSH or 100-mM NAC. Results of panel A and
panel B are pooled from 4 independent Ellman’s assays. (C) SH-oxidation of individual myocardial proteins as in Figure 3B. SH oxidation of myocardial
proteins at selected molecular weights were noticed in a non-uniform fashion following the application of 2.5-mM DTDP. Subsequent application of 
10-mM GSH, 10-mM NAC or 10-mM DTT gave similar results with the Elmman’s assays. Assays of panel C were repeated 4 times.
8[22]. In contrast, the DTDP-evoked reduction in force was corre-
lated with the oxidation of the sarcomeric actin and myosin light
chain 1 [23]. The divergent involvement of sarcomeric protein
modifications following peroxynitrite or DTDP applications may
explain why cross-bridge kinetics was not altered following perox-
ynitrite exposures, while it was largely affected by DTDP. Our effort
to identify a hypothetical group of proteins undergoing selective
oxidation-reduction cycles by peroxynitrite and antioxidant expo-
sures was precluded by the homogenous and the relatively small
changes in signal intensities even at maximal peroxynitrite con-
centrations in our biotinylation assays. Hence, in this study we
could not ascribe the peroxynitrite-evoked SH oxidation-depend-
ent mechanical changes to one or another sarcomeric protein.
One of the salient aims of our present investigation was to
compare the relative potentials of different reducing agents in
reverting SH-dependent mechanical alterations in human car-
diomyocytes. To this end, following peroxynitrite or DTDP admin-
istrations assays were performed with DTT, NAC and with the
intracellular antioxidant GSH. In general, DTT possessed the high-
est potential in the reversion of the mechanical and biochemical
effects. On the other hand, the results obtained with GSH and NAC
were seemingly contradictious. After DTDP, both of these latter
reducing agents induced a modest increase in the SH content.
Interestingly, however these resulted in further diminution in Fo
and in ktr,max, and significant increases in Fpassive. However, after
peroxynitrite, NAC similarly to DTT evoked a partial reversion in Fo.
Redox reactions in the cells are determined by many factors,
among which are probably the most important the redox potential,
the conformation and the molecular size of the reacting partners.
Additionally, SH oxidizing agents can react in different ways with
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Fig. 5 Reversion of the mechanical effects evoked by 2.5-mM DTDP following the applications of SH-reducing agents. (A) Original recordings illustrate
the mechanical effects of the sequentially applied 2.5-mM DTDP and 10-mM DTT (upper panel) and 2.5-mM DTDP and 10-mM NAC (lower panel). Bar
graphs (means  S.E.M.) illustrate the magnitudes of relative changes in Fo (B), Fpassive (C) and in ktr,max (D). DTDP decreased Fo, evoked a small
increase in Fpassive and decreased ktr,max. DTT induced an almost complete restoration in Fo and ktr,max, and was without effects on Fpassive. On the other
hand, GSH or NAC induced a decreased Fo and ktr,max further, and evoked an increase in Fpassive. The number of cardiomyocytes ranged between 8 and
26 for the different tests.
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the thiol groups of the proteins, generating intra- or intermolecu-
lar disulfide bridges or mixed disulfides. For example, DTDP
besides generating disulfide bonds inside and among the proteins
can also create a mixed disulfide between the cysteinil residues
and one-half of the DTDP molecules, thereby liberating the other
halves of DTDP molecules as thiopyridones [24]. DTT, due to its
low redox potential, can reduce disulfides very rapidly and with a
high efficiency seemingly irrespectively of the presence or
absence of mixed disulfides [42]. Conversely, GSH and NAC, both
having higher redox potentials than DTT, are less effective in
reducing the different forms of oxidized SH groups. We assume,
therefore, that these differences can contribute to the explanation
of the complex interplay between oxidative and reducing agents
included in our experiments. Although there are positive human
studies with antioxidants, including NAC [43], the results of big
clinical trials with antioxidants in preventing the initiation and pro-
gression of cardiovascular diseases are also variable [44–46]. The
human clinical trials ended with negative outcomes and the results
of this study emphasize the significance of the proper application
and choice of antioxidants.
In conclusion, results of this model investigation revealed that
the contribution of SH oxidation to the peroxynitrite-mediated con-
tractile depression is inferior to other peroxynitrite-evoked bio-
chemical effects in human cardiomyocytes. Our data also illustrat-
ed that Ca2-activated active force, Ca2-independent passive
force and the kinetics of the actin-myosin cycle are in complex rela-
tions with myocardial protein oxidation. Different combinations of
the reduced and oxidized myocardial proteins may exert opposing
effects on these parameters. Hence, the extent of myocardial pro-
tein oxidation, and the molecular characteristics of the oxidoreduc-
tive insults should be also considered when the SH-dependent
mechanical alterations are evaluated in human cardiomyocytes.
Acknowledgements
This study was supported by OTKA K68363, ETT 449/2006, OTKA F48873
and OTKA K72315 grants. Zoltán Papp and Attila Tóth hold Bolyai
Fellowships of the Hungarian Academy of Sciences.
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
References
1. Finkel MS, Oddis CV, Jacob TD, Watkins
SC, Hattler BG, Simmons RL. Negative
inotropic effects of cytokines on the heart
mediated by nitric oxide. Science. 1992;
257: 387–9.
2. Wang P, Zweier JL. Measurement of nitric
oxide and peroxynitrite generation in the
postischemic heart. Evidence for peroxyni-
trite-mediated reperfusion injury. J Biol
Chem. 1996; 271: 29223–30.
3. Nonami Y. The role of nitric oxide in car-
diac ischemia-reperfusion injury. Jpn Circ
J. 1997; 61: 119–32.
4. Weinstein DM, Mihm MJ, Bauer JA.
Cardiac peroxynitrite formation and left
ventricular dysfunction following doxoru-
bicin treatment in mice. J Pharmacol Exp
Ther. 2000; 294: 396–401.
5. Ferdinandy P, Danial H, Ambrus I,
Rothery RA, Schulz R. Peroxynitrite is a
major contributor to cytokine-induced
myocardial contractile failure. Circ Res.
2000; 87: 241–7.
6. Dhalla NS, Temsah RM, Netticadan T.
Role of oxidative stress in cardiovascular
diseases. J Hypertens. 2000; 18: 655–73.
7. Okamoto T, Akaike T, Sawa T, Miyamoto
Y, van der Vliet A, Maeda H. Activation of
matrix metalloproteinases by peroxynitrite-
induced protein S-glutathiolation via disul-
fide S-oxide formation. J Biol Chem. 2001;
276: 29596–602.
8. Hare JM, Stamler JS. NO/redox disequi-
librium in the failing heart and cardiovas-
cular system. J Clin Invest. 2005; 115:
509–17.
9. Goswami SK, Maulik N, Das DK.
Ischemia-reperfusion and cardioprotec-
tion: a delicate balance between reactive
oxygen species generation and redox
homeostasis. Ann Med. 2007; 39: 275–89.
10. Canton M, Neverova I, Menabo R, Van Eyk
J, Di Lisa F. Evidence of myofibrillar protein
oxidation induced by postischemic reperfu-
sion in isolated rat hearts. Am J Physiol
Heart Circ Physiol. 2004; 286: H870–H877.
11. Giordano FJ. Oxygen, oxidative stress,
hypoxia, and heart failure. J Clin Invest.
2005; 115: 500–8.
12. Posterino GS, Lamb GD. Effects of reduc-
ing agents and oxidants on excitation-con-
traction coupling in skeletal muscle fibres of
rat and toad. J Physiol. 1996; 496: 809–25.
13. Powell SR, Gurzenda EM, Wahezi SE.
Actin is oxidized during myocardial
ischemia. Free Radic Biol Med. 2001; 30:
1171–6.
14. Katori T, Donzelli S, Tocchetti CG,
Miranda KM, Cormaci G, Thomas DD,
Ketner EA, Lee MJ, Mancardi D, Wink
DA, Kass DA, Paolocci N. Peroxynitrite
and myocardial contractility: in vivo versus
in vitro effects. Free Radic Biol Med. 2006;
41: 1606–18.
15. Ferdinandy P. Peroxynitrite: just an oxida-
tive/nitrosative stressor or a physiological
regulator as well? Br J Pharmacol. 2006;
148: 1–3.
16. Reiter CD, Teng RJ, Beckman JS.
Superoxide reacts with nitric oxide to
nitrate tyrosine at physiological pH via per-
oxynitrite. J Biol Chem. 2000; 275:
32460–6.
17. Forman HJ, Fukuto JM, Torres M. Redox
signaling: thiol chemistry defines which
reactive oxygen and nitrogen species can
act as second messengers. Am J Physiol
Cell Physiol. 2004; 287: C246–56.
18. Stamler JS. Redox signaling: nitrosylation
and related target interactions of nitric
oxide. Cell. 1994; 78: 931–6.
19. Thomas JA, Poland B, Honzatko R.
Protein sulfhydryls and their role in the
antioxidant function of protein S-thiolation.
Arch Biochem Biophys. 1995; 319: 1–9.
20. Ceconi C, Bernocchi P, Boraso A,
Cargnoni A, Pepi P, Curello S, Ferrari R.
New insights on myocardial pyridine
nucleotides and thiol redox state in
ischemia and reperfusion damage.
Cardiovasc Res. 2000; 47: 586–94.
21. Eaton P, Wright N, Hearse DJ, Shattock
MJ. Glyceraldehyde phosphate dehydroge-
nase oxidation during cardiac ischemia
and reperfusion. J Mol Cell Cardiol. 2002;
34: 1549–60.
10
22. Borbely A, Toth A, Edes I, Virag L, Papp
JG, Varro A, Paulus WJ, van der Velden
J, Stienen GJM, Papp Z. Peroxynitrite-
induced alpha-actinin nitration and con-
tractile alterations in isolated human
myocardial cells. Cardiovasc Res. 2005;
67: 225–33.
23. Hertelendi Z, Toth A, Borbely A, Galajda
Z, van der Velden J, Stienen GJM, Edes
I, Papp Z. Oxidation of myofilament pro-
tein sulfhydryl groups reduces the con-
tractile force and its Ca2 sensitivity in
human cardiomyocytes. Antioxid Redox
Signal. 2008; 10: 1175–84.
24. Lamb GD, Posterino GS. Effects of oxida-
tion and reduction on contractile function
in skeletal muscle fibres of the rat. J
Physiol. 2003; 546: 149–63.
25. Papp Z, Szabo A, Barends JP, Stienen
GJM. The mechanism of the force
enhancement by MgADP under simulat-
ed ischaemic conditions in rat cardiac
myocytes. J Physiol. 2002; 543:
177–89.
26. van der Velden J, Klein LJ, Zaremba R,
Boontje NM, Huybregts MA, Stooker W,
Eijsman L, de Jong JW, Visser CA, Visser
FC, Stienen GJM. Effects of calcium, inor-
ganic phosphate, and pH on isometric
force in single skinned cardiomyocytes
from donor and failing human hearts.
Circulation. 2001; 104: 1140–6.
27. Fan D, Wannenburg T, de Tombe PP.
Decreased myocyte tension development
and calcium responsiveness in rat right
ventricular pressure overload. Circulation.
1997; 95: 2312–7.
28. Fabiato A, Fabiato F. Calculator programs
for computing the composition of the solu-
tions containing multiple metals and lig-
ands used for experiments in skinned
muscle cells. J Physiol. 1979; 75:
463–505.
29. Szilagyi S, Pollesello P, Levijoki J,
Kaheinen P, Haikala H, Edes I, Papp Z.
The effects of levosimendan and 
OR-1896 on isolated hearts, myocyte-
sized preparations and phos-
phodiesterase enzymes of the guinea 
pig. Eur J Pharmacol. 2004; 486: 
67–74.
30. Riddles PW, Blakeley RL, Zerner B.
Reassessment of Ellman’s reagent.
Methods Enzymol. 1983; 91: 49–60.
31. Humphries KM, Pennypacker JK, Taylor
SS. Redox regulation of cAMP-dependent
protein kinase signaling: kinase versus
phosphatase inactivation. J Biol Chem.
2007; 282: 22072–9.
32. Sims C, Harvey RD. Redox modulation of
basal and beta-adrenergically stimulated
cardiac L-type Ca(2) channel activity by
phenylarsine oxide. Br J Pharmacol. 2004;
142: 797–807.
33. Marczin N, El Habashi N, Hoare GS,
Bundy RE, Yacoub M. Antioxidants in
myocardial ischemia-reperfusion injury:
therapeutic potential and basic mecha-
nisms. Arch Biochem Biophys. 2003; 420:
222–36.
34. Giustarini D, Rossi R, Milzani A,
Colombo R, Dalle-Donne I. S-glutathiony-
lation: from redox regulation of protein
functions to human diseases. J Cell Mol
Med. 2004; 8: 201–12.
35. Schafer FQ, Buettner GR. Redox environ-
ment of the cell as viewed through the
redox state of the glutathione disul-
fide/glutathione couple. Free Radic Biol
Med. 2001; 30: 1191–212.
36. Eaton P, Byers HL, Leeds N, Ward MA,
Shattock MJ. Detection, quantitation,
purification, and identification of cardiac
proteins S-thiolated during ischemia and
reperfusion. J Biol Chem. 2002; 277:
9806–11.
37. Dean RT, Fu S, Stocker R, Davies MJ.
Biochemistry and pathology of radical-
mediated protein oxidation. Biochem J.
1997; 324: 1–18.
38. Bolli R, Marban E. Molecular and cellular
mechanisms of myocardial stunning.
Physiol Rev. 1999; 79: 609–34.
39. Mallis RJ, Buss JE, Thomas JA. Oxidative
modification of H-ras: S-thiolation and 
S-nitrosylation of reactive cysteines.
Biochem J. 2001; 355: 145–53.
40. Kaplan P, Babusikova E, Lehotsky J,
Dobrota D. Free radical-induced protein
modification and inhibition of Ca2-
ATPase of cardiac sarcoplasmic reticulum.
Mol Cell Biochem. 2003; 248: 41–7.
41. Pfeiffer S, Gorren AC, Schmidt K, Werner
ER, Hansert B, Bohle DS, Mayer B.
Metabolic fate of peroxynitrite in aqueous
solution. Reaction with nitric oxide and
pH-dependent decomposition to nitrite and
oxygen in a 2:1 stoichiometry. J Biol
Chem. 1997; 272: 3465–70.
42. Cleland WW. Dithiothreitol, a new protec-
tive reagent for SH groups. Biochemistry.
1964; 3: 480–2.
43. Koramaz I, Pulathan Z, Usta S, Karahan
SC, Alver A, Yaris E, Kalyoncu NI, Ozcan
F. Cardioprotective effect of cold-blood
cardioplegia enriched with N-acetylcys-
teine during coronary artery bypass graft-
ing. Ann Thorac Surg. 2006; 81: 613–8.
44. Griendling KK, FitzGerald GA. Oxidative
stress and cardiovascular injury: Part II:
animal and human studies. Circulation.
2003; 108: 2034–40.
45. Munteanu A, Zingg JM, Azzi A. Anti-ather-
osclerotic effects of vitamin E–myth or
reality? J Cell Mol Med. 2004; 8: 59–76.
46. Ceconi C, Boraso A, Cargnoni A, Ferrari
R. Oxidative stress in cardiovascular dis-
ease: myth or fact? Arch Biochem
Biophys. 2003; 420: 217–21.
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
Author Queries
Q1 Author: An Exclusive Licence Form has not yet been received for this paper.  Please go to: http://www.blackwellpublishing.com/
pdf/JCMM_ELF.pdf and download and complete a form and return it to the Production Editor along with your corrections to the proofs.  Note
that we cannot publish your paper until the form is received.
